• In recent weeks, Oscar Health has drawn attention ahead of its upcoming earnings release, as analysts project a substantial year-on-year EPS improvement alongside continued revenue growth and margin gains reported over the last several years.
• Commentary now frames Oscar as a scaled, infrastructure-like healthcare platform with a stronger balance sheet, expanding market share and improving free cash flow, reshaping how investors assess its path toward sustainable profitability.
• Next, we’ll examine how expectations for better profitability and operational efficiency could reshape Oscar Health’s existing investment narrative.

Find 55 companies with promising cash flow potential yet trading below their fair value.

Oscar Health Investment Narrative Recap

To own Oscar Health, you have to believe its tech-first insurance model can convert rapid revenue and membership growth into durable profitability, even after a sharp share price pullback. The latest earnings expectations, with projected EPS improvement and ongoing margin gains, keep the near term profitability inflection as the key catalyst, while the biggest risk remains whether medical costs and pricing decisions allow that margin story to hold. The new information does not materially change that balance today.

The most relevant recent development here is Oscar’s reaffirmed 2026 guidance for US$18.7–US$19.0 billion in revenue and US$250–US$450 million in earnings from operations. Against the backdrop of a stock that is down more than 30% since late 2025, that guidance anchors the profitability narrative that analysts are watching into the upcoming results and frames how much room there could be for estimate revisions if trends in medical costs, pricing, or membership growth differ from expectations.

Yet, even with this improving margin story, investors should be aware that rising medical loss ratios and tighter regulatory scrutiny on premium hikes could still...

Oscar Health's narrative projects $12.4 billion revenue and $245.4 million earnings by 2028. This requires 4.9% yearly revenue growth and about a $406.6 million earnings increase from -$161.2 million today.

Uncover how Oscar Health's forecasts yield a $15.78 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a far more cautious picture, assuming revenue could shrink about 0.7% a year and only reach around US$11.0 billion by 2028, so if you are encouraged by the latest EPS improvement signals, it is worth comparing that optimism with this pessimistic scenario and deciding which set of assumptions feels more realistic as new earnings data come through.

Explore 20 other fair value estimates on Oscar Health - why the stock might be worth 6% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oscar Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.